TEX46 and neoplasm: TEX have a potential to meet this need, and profiling of TEX cargos by proteomics or transcriptomics offers a window of opportunity for validation of TEX as cancer biomarkers that potentially may exceed circulating tumor cells (CTC) and circulating free DNA (sfDNA) in the detection of minimal residual disease (MRD) or in predicting responses to therapy.